PT  - JOURNAL ARTICLE
AU  - Freedberg, Daniel E.
AU  - Conigliaro, Joseph
AU  - Sobieszczyk, Magdalena E.
AU  - Markowitz, David D.
AU  - Gupta, Aakriti
AU  - O’Donnell, Max R.
AU  - Li, Jianhua
AU  - Tuveson, David A.
AU  - Jin, Zhezhen
AU  - Turner, William C.
AU  - Landry, Donald W.
AU  - Wang, Timothy C.
AU  - Tracey, Kevin J.
AU  - Callahan, Michael V.
AU  - Abrams, Julian A.
TI  - Famotidine Use is Associated with Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study
AID  - 10.1101/2020.05.01.20086694
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.05.01.20086694
4099  - http://medrxiv.org/content/early/2020/05/19/2020.05.01.20086694.short
4100  - http://medrxiv.org/content/early/2020/05/19/2020.05.01.20086694.full
AB  - Background and Aims No medications are proven to improve clinical outcomes in COVID-19. Famotidine is commonly used for gastric acid suppression but has recently gained attention as an antiviral that may inhibit SARS-CoV-2 replication. This study tested whether famotidine use is associated with improved clinical outcomes in patients with COVID-19 initially hospitalized to a non-intensive care setting.Methods This was retrospective cohort study conducted among consecutive hospitalized patients with COVID-19 infection from February 25 to April 13, 2020 at a single medical center. The primary exposure was famotidine, received within 24 hours of hospital admission. The primary outcome was intubation or death. Propensity score matching was used to balance the baseline characteristics of patients who did and did not use famotidine.Results 1,620 hospitalized patients with COVID-19 were identified including 84 (5.1%) who received famotidine within 24 hours of hospital admission. 340 (21%) patients met the study composite outcome of death or intubation. Use of famotidine was associated with reduced risk for death or intubation (adjusted hazard ratio (aHR) 0.42, 95% CI 0.21-0.85) and also with reduced risk for death alone (aHR 0.30, 95% CI 0.11-0.80). After balancing baseline patient characteristics using propensity score matching, these relationships were unchanged (HR for famotidine and death or intubation 0.43, 95% CI 0.21-0.88). Proton pump inhibitors, which also suppress gastric acid, were not associated with reduced risk for death or intubation.Conclusion Famotidine use is associated with reduced risk of intubation or death in hospitalized COVID-19 patients. Randomized controlled trials are warranted to determine whether famotidine therapy improves outcomes in hospitalized COVID-19 patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was unfunded.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be made available by the corresponding author upon request, with appropriate safeguards for patient privacy.